Injuries and the Mets? A tale as old as time. Ronny Mauricio’s ACL surgery and Tyrone Taylor’s multiple procedures left the team battling setbacks early in 2024. Now, the $22 million gamble on A.J. Minter adds another chapter to their injury-riddled saga. With the lefty reliever recovering from hip surgery, the Mets are walking a tightrope between rushing him back and ensuring he stays healthy for the long haul.

A.J. Minter’s baseball journey took a sharp turn in August 2024. While still with the Braves, he struggled with persistent hip pain, and after months of discomfort, he finally underwent surgery to repair a torn labrum in his left hip. It was a tough blow for the reliever, one that sidelined him for the remainder of the season. But despite the injury, the Mets saw something in him, signing him to a two-year, $22 million contract in hopes that he could return to his dominant form. The gamble came with high stakes—Minter’s health was uncertain, and post-surgical recoveries are always unpredictable.

But Minter wasn’t one to back down. He dedicated himself to a strict rehab regimen, gradually regaining strength and refining his mechanics. Then, in March 2025, a defining moment arrived—he faced live hitters for the first time since his surgery, signaling a major step in his recovery. The Mets bullpen, already in need of reliable arms, felt the impact of his return, but the team is being careful. Rushing him back could mean risking another setback, but waiting too long could leave them shorthanded. As the season inches closer, the real test remains: Can Minter live up to the faith the Mets have placed in him?

Will A.J. Minter anchor the Mets’ bullpen?

It is true that A.J. Minter has faced live batters, a vital step in his recovery. However, the real issue remains—how effective will the pitcher be when it truly counts? MLB history is led by talents who returned from surgery just to struggle. For instance, Alex Rodriguez had multiple hip replacements, and after that, his performance dramatically declined. In addition, after shoulder surgery, Johan Santana, who was once a formidable force on the mound, never fully recovered to his Cy Young-level capabilities. Chase Utley, who battled knee issues, found it tough to regain his peak. While medical surgeries have enhanced recovery outcomes, the unpredictability of postsurgery performance still looms large.

If Minter does not provide at full capability, the Mets need to turn to their bullpen depth. Fortunately, the team has a mix of experienced and enhancing talents to lean on. Edwin Díaz, the team’s dominant closer, will be vital. However, his role is already placed in the ninth inning. In addition, Sean Manaea and Frankie Montas Jr. bring veteran starting experience. There are relievers, like Reed Garrett and Drew Smith, who could be utilized in high-leverage situations. Younger talents like José Buttó and Christian Scott also provide intriguing options. However, none provide the same left-handed availability A.J. Minter brings, leaving the Mets with a tricky bullpen puzzle to solve.

A.J. Minter’s journey from injury to recovery epitomizes the issues and triumphs that professional athletes face. The Mets’ strategic investment in his talent, coupled with a prudent approach to his rehabilitation, highlights a commitment to player welfare and team success. As the season unfolds, Minter’s performance will be a testament to resilience and the meticulous planning that underpins a successful comeback.